Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: A randomized pilot trial of the Hoosier Oncology Group

Journal of Clinical Oncology

Volumn 17, Issue 10, 1999, Pages 3033-3037

  Miller, Kathy D ^a   McCaskill Stevens, Worta ^a   Sisk, Judy ^a   Loesch, David M ^a   Monaco, Frank ^a   Seshadri, Roopa ^a   Sledge Jr , George W ^a  

^a Hoosier Oncology Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER STAGING; CARCINOMA IN SITU; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 0032885642     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1999.17.10.3033     Document Type: Article

References (25)

1. Fisher B, Suffer E, Rudock C, et al: Presence of a growth stimulating factor in serum following primary tumor removal in mice. Cancer Res 49:1996-2001, 1989
2. Fisher B, Saffer E, Rudock C, et al: Effect of local or systemic treatment prior to primary tumor removal on the production and response to a serum growth stimulating factor in mice. Cancer Res 49:2002-2004, 1989
3. Buzdar A, Singletary S, Booser D, et al: Combined modality treatment of stage III and inflammatory breast cancer: M.D. Anderson Cancer Center experience. Surg Oncol Clin N Am 4:715-734, 1995
4. Bonadonna G, Valagussa P, Brambilla C, et al: Primary chemotherapy in operable breast cancer: Eight-year experience at the Milan Cancer Institute. J Clin Oncol 16:93-100, 1998
5. Singletary S, McNeese M, Hortobagyi G: Feasibility of breast-conservation surgery after induction chemotherapy for locally advanced breast cancer. Cancer 69:2849-2852, 1992
6. Scholl S, Pierga J, Asselain B, et al: Breast tumor response to primary chemothrapy predicts local and distant control as well as survival. Eur J Cancer 31A:1969-1975, 1995
7. Valagussa P, Zambetti M, Bonadonna G, et al: Prognostic factors in locally advanced noninflammatory breast cancer: Long term results following primary chemotherapy. Breast Cancer Res Treat 15:137-147, 1990
8. Laing K, Ragaz J, Le N, et al: Correlation of modified radical mastectomy (MRM) with outcome of stage III breast cancer patients (SIIIBRCA) treated with preoperative therapy (NEO): Is there a need for randomized trials? Analysis of the British Columbia (BC) Study. Proc Am Soc Clin Oncol 17:168a. 1998 (abstr 647)
9. Norton L, Simon R: Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep 61:1307-1317, 1977
10. Norton L: A gompertzian model of human breast cancer growth. Cancer Res 48:7067-7071, 1988
11. Hudis C, Seidman A, Baselga J, et al: Sequential high dose adjuvant doxorubicin, paclitaxel, and cyclophosphamide with G-CSF is feasible for women with resected breast cancer and >4(+) lymph nodes. Proc Am Soc Clin Oncol 13:65, 1994 (abstr)
12. Hudis C, Seidman A, Raptis G, et al: Sequential doxorubicin, paclitaxel, and cyclophosphamide in women with resected breast cancer and >4(+) lymoh nodes. Proc Am Soc Clin Oncol 14:113, 1995 (abstr)
13. Valero V, Holmes FA, Walters RS, et al: Phase II trial of docetaxel: A new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 13:2886-2894, 1995
14. Ravdin PM, Burris HA III, Cook G, et al: Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 13:2879-2885, 1995
15. Misset J, Dieras V, Bozec L, et al: Long term follow up of the phase I/II study of docetaxel and doxorubicin as 1st line chemotherapy of metastatic breast cancer. Proc Am Soc Clin Oncol 17:160,1998 (abstr)
16. Herrada J, Iyer RB, Atkinson EN, et al: Relative value of physical examination, mammography, and breast sonography in evaluating the size of the primary tumor and regional lymph node metastases in women receiving neoadjuvant chemotherapy for locally advanced breast carcinoma. Clin Cancer Res 3:1565-1569, 1997
17. Mencel P, Nahum K, Lerner W, et al: Adjuvant chemotherapy of sequential docetaxel and Adriamycin in patients with completely resected breast cancer: Preliminary report. Proc Am Soc Clin Oncol 18:99a, 1999 (abstr)
18. Laurence V, Extra J, Girre V, et al: Phase II study of sequential docetaxel and doxorubicin as primary chemotherapy for large operable breast cancer. Proc Am Soc Clin Oncol 18:98a, 1999 (abstr)
19. Ragaz J, Baird R, Rebbeck P, et al: Preoperative (neoadjuvant) versus postoperative adjuvant chemotherapy for stage I-II breast cancer: Long-term analysis of British Columbia randomized trial. Proc Am Soc Clin Oncol 16:142a, 1997 (abstr)
20. Semiglazov V, Topuzov E, Bavli J, et al: Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone on stge IIb-IIIa breast cancer. Ann Oncol 5:591-595, 1994
21. Mauriac L, Durand M, Avril A, et al: Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Ann Oncol 2:347-354, 1991
22. Mauriac L, MacGrogan G, Avril A, et al: Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: A unicentre randomized trial with 124-month median follow-up. Ann Oncol 10:47-52, 1999
23. Scholl S, Fourquet A, Asselain B, et al: Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumors considered too large for breast conserving surgery: Preliminary results of a randomised trial: S6. Eur J Cancer 30A:645-652, 1994
24. Makris A, Powles T, Ashley S, et al: A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol 9:1179-1184, 1998
25. Fisher B, Bryant J, Wolmark N, et al: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672-2685, 1998